Additionally, the companies have agreed on an exclusive negotiation period for rights to Pollinex Quattro in Canada for the treatment of grass, ragweed and tree allergies. Pollinex Quattro is an adjuvanted vaccine and has a dosing course of four injections.
Nycomed will support Allergy Therapeutics in its efforts to submit the dossier for Pollinex Quattro Grass in the first half of 2009. Allergy Therapeutics will work on the submission of Pollinex Quattro Ragweed in the second half of 2009. Completion of clinical development and submission of Pollinex Quattro Tree is subject to final agreement.
Joost van der Mark, vice president of business development at Nycomed Canada, said: “Nycomed is very pleased to add Pollinex R, to its portfolio of products that can help Canadians who struggle with allergies. This agreement with Allergy Therapeutics reinforces that Nycomed is a company committed to developing relationships with business partners that can make a meaningful difference to Canadians.”